Non Hodgkin's Lymphoma News and Research

RSS
The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.
Halozyme first quarter net loss increases to $15.1 million

Halozyme first quarter net loss increases to $15.1 million

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Gilead commences GS-1101 Phase 3 trial in CLL

Gilead commences GS-1101 Phase 3 trial in CLL

CTI first quarter net loss decreases 66% to $17.4 million

CTI first quarter net loss decreases 66% to $17.4 million

ImmunoGen commences IMGN529 Phase I trial in NHL

ImmunoGen commences IMGN529 Phase I trial in NHL

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Spectrum signs definitive agreement to acquire Allos

Spectrum signs definitive agreement to acquire Allos

Routine counseling on fertility preservation needed for young women with cancer

Routine counseling on fertility preservation needed for young women with cancer

New drug makes chemotherapy more effective in treating acute myeloid leukemia

New drug makes chemotherapy more effective in treating acute myeloid leukemia

CTI fourth quarter net loss decreases to $17.9 million

CTI fourth quarter net loss decreases to $17.9 million

Northern Ireland has higher survival rates for pancreatic cancer, leukaemia

Northern Ireland has higher survival rates for pancreatic cancer, leukaemia

New immunotherapy combination prolongs survival in dogs with NHL

New immunotherapy combination prolongs survival in dogs with NHL

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Cell Therapeutics voluntarily withdraws Pixuvri NDA for NHL

Cell Therapeutics voluntarily withdraws Pixuvri NDA for NHL

Amgen enters definitive merger agreement to acquire Micromet

Amgen enters definitive merger agreement to acquire Micromet

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

FLT-PET imaging can effectively detect mantle cell lymphoma

FLT-PET imaging can effectively detect mantle cell lymphoma

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB initiates EXXELERATE study in rheumatoid arthritis

Wistar to develop new drug against EBV-associated cancers

Wistar to develop new drug against EBV-associated cancers